EA201990976A1 - Новый способ профилактического лечения непроизвольной потери массы - Google Patents

Новый способ профилактического лечения непроизвольной потери массы

Info

Publication number
EA201990976A1
EA201990976A1 EA201990976A EA201990976A EA201990976A1 EA 201990976 A1 EA201990976 A1 EA 201990976A1 EA 201990976 A EA201990976 A EA 201990976A EA 201990976 A EA201990976 A EA 201990976A EA 201990976 A1 EA201990976 A1 EA 201990976A1
Authority
EA
Eurasian Patent Office
Prior art keywords
incidental
new method
mass loss
preventive treatment
cachexia
Prior art date
Application number
EA201990976A
Other languages
English (en)
Inventor
Агнес Коль
Ральф Ленхард
Original Assignee
Аоп Орфан Фармасьютикалз Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аоп Орфан Фармасьютикалз Аг filed Critical Аоп Орфан Фармасьютикалз Аг
Publication of EA201990976A1 publication Critical patent/EA201990976A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем изобретении предложено новое применение каннабиноидов для предотвращения пре-кахексии или кахексии у пациента, страдающего раком, отличающееся тем, что указанный каннабиноид вводят в низких дозах, и отличающееся тем, что введение начинают до химиотерапии и поддерживают, по меньшей мере, в течение химиотерапии.
EA201990976A 2016-11-24 2017-11-24 Новый способ профилактического лечения непроизвольной потери массы EA201990976A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16200498 2016-11-24
PCT/EP2017/080353 WO2018096100A1 (en) 2016-11-24 2017-11-24 Cannabinoids for prophylactic treatment of involuntary weight loss

Publications (1)

Publication Number Publication Date
EA201990976A1 true EA201990976A1 (ru) 2019-12-30

Family

ID=57394468

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990976A EA201990976A1 (ru) 2016-11-24 2017-11-24 Новый способ профилактического лечения непроизвольной потери массы

Country Status (14)

Country Link
US (2) US10940136B2 (ru)
EP (2) EP3954366A1 (ru)
CA (1) CA3044880A1 (ru)
DK (1) DK3544598T3 (ru)
EA (1) EA201990976A1 (ru)
ES (1) ES2899946T3 (ru)
HR (1) HRP20212003T8 (ru)
HU (1) HUE056947T2 (ru)
IL (1) IL266838B (ru)
LT (1) LT3544598T (ru)
PL (1) PL3544598T3 (ru)
PT (1) PT3544598T (ru)
SI (1) SI3544598T1 (ru)
WO (1) WO2018096100A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3235080A1 (en) 2021-10-26 2023-04-05 Alexandra M CAPANO Methods of treating endometriosis and other non-cancer gynecological disorders with hemp extract
US11793847B2 (en) 2021-10-26 2023-10-24 Ecofibre USA Inc. Methods of treating endometrial cancer using hemp extract

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2450493A (en) * 2007-06-25 2008-12-31 Gw Pharma Ltd Cannabigerol for use in treatment of diseases benefiting from agonism of CB1 and CB2 cannabinoid receptors
AU2011333683A1 (en) 2010-11-25 2013-05-09 Aop Orphan Pharmaceuticals Ag Fast disintegrating compositions comprising nabilone and randomly methylated beta cyclodextrin

Also Published As

Publication number Publication date
US10940136B2 (en) 2021-03-09
PL3544598T3 (pl) 2022-02-07
HRP20212003T8 (hr) 2022-04-29
IL266838A (en) 2019-08-29
HRP20212003T1 (hr) 2022-04-01
EP3544598A1 (en) 2019-10-02
IL266838B (en) 2022-07-01
PT3544598T (pt) 2021-12-06
HUE056947T2 (hu) 2022-04-28
LT3544598T (lt) 2022-01-25
SI3544598T1 (sl) 2022-02-28
EP3544598B1 (en) 2021-10-06
WO2018096100A1 (en) 2018-05-31
CA3044880A1 (en) 2018-05-31
DK3544598T3 (da) 2022-01-03
EP3954366A1 (en) 2022-02-16
ES2899946T3 (es) 2022-03-15
US20210212985A1 (en) 2021-07-15
US20190388383A1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
EA201890159A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ГЕМАТОЛОГИЧЕСКОГО ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ С ПОМОЩЬЮ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
MX2017005929A (es) Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
ECSP17073878A (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
MX2020010689A (es) Defibrotida para la prevencion y tratamiento del sindrome de liberacion de citocinas y la neurotoxicidad asociada con la inmunodeplecion.
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
MD20170073A2 (ru) Комбинированные терапии для лечения раковых заболеваний
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2019002510A (es) Metodos para usar un anticuerpo biespecifico que reconoce el factor de coagulacion ix y/o el factor de coagulacion ix activado y el factor de coagulacion x y/o factor de coagulacion x activado.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
EA201791736A1 (ru) Комбинированная терапия для лечения рака
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
EA201692436A1 (ru) Медицинское применение
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
EA201691555A1 (ru) Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени
BR112017013982A2 (pt) fármaco de combinação
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
AR119159A1 (es) Tratamientos de angioedema
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
EA202191358A1 (ru) Новые соединения и их применение в лечении
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
EA201990976A1 (ru) Новый способ профилактического лечения непроизвольной потери массы
EA201891968A1 (ru) Комбинированное лечение с использованием liv1-adc и химиотерапевтического средства